MicroRNA-326 inhibits cell proliferation and invasion, activating apoptosis in hepatocellular carcinoma by directly targeting LIM and SH3 protein 1 Retraction in /10.3892/or.2023.8524

Hu,Shiping; Ran,Yun; Chen,Wenlin; Zhang,Yuncheng; Xu,Yongjian

doi:10.3892/or.2017.5810

MicroRNA-326 inhibits cell proliferation and invasion, activating apoptosis in hepatocellular carcinoma by directly targeting LIM and SH3 protein 1

Retraction in: /10.3892/or.2023.8524

Authors:
- Shiping Hu
- Yun Ran
- Wenlin Chen
- Yuncheng Zhang
- Yongjian Xu
View Affiliations

Affiliations: Department of Hepatology, Longgang Hospital of Traditional Chinese Medicine, Shenzhen, Guangdong 518172, P.R. China
Published online on: July 12, 2017 https://doi.org/10.3892/or.2017.5810
Pages: 1569-1578

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is the fifth-most common cancer and third leading cause of cancer-related deaths worldwide. Increasing evidence indicates that dysregulation of microRNAs is often observed in HCC, and has been extensively investigated in terms of cancer formation, progression, diagnosis, therapy, and prognosis. Recently, microRNA-326 (miR-326) has been demonstrated to play important roles in multiple types of human cancer. However, the expression pattern, clinical significance, roles and regulatory mechanisms of miR-326 in HCC have yet to be elucidated. In this study, miR-326 was frequently downregulated in HCC tissues and cell lines. Low miR-326 expression was significantly associated with the TNM stage, differentiation and lymph node metastasis of HCC patients. Further functional assays demonstrated that the recovered miR-326 expression inhibited HCC cell proliferation and invasion and activated cell apoptosis in vitro. In addition, LIM and SH3 protein 1 (LASP1) was identified as a direct target gene of miR-326 in HCC. Furthermore, LASP1 was upregulated in HCC tissues and cell lines. The expression level of LASP1 mRNA was inversely correlated with that of miR-326 in HCC tissues. Moreover, LASP1 silencing elicited effects similar to miR-326 overexpression on HCC cells, and LASP1 upregulation markedly reversed the effects of miR-326 overexpression on HCC cells. These results revealed that miR-326 suppressed the progression of HCC by directly targeting LASP1. Therefore, miR-326 may be used as a potential therapeutic target for the treatment of patients with HCC.

View Figures

View References

1	Kansagara D, Papak J, Pasha AS, O'Neil M, Freeman M, Relevo R, Quiñones A, Motu'apuaka M and Jou JH: Screening for hepatocellular carcinoma in chronic liver disease: A systematic review. Ann Intern Med. 161:261–269. 2014. View Article : Google Scholar : PubMed/NCBI
2	Sanyal AJ, Yoon SK and Lencioni R: The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist. 15:(Suppl 4). 14–22. 2010. View Article : Google Scholar : PubMed/NCBI
3	Tejeda-Maldonado J, García-Juárez I, Aguirre-Valadez J, González-Aguirre A, Vilatobá-Chapa M, Armengol-Alonso A, Escobar-Penagos F, Torre A, Sánchez-Ávila JF and Carrillo-Pérez DL: Diagnosis and treatment of hepatocellular carcinoma: An update. World J Hepatol. 7:362–376. 2015. View Article : Google Scholar : PubMed/NCBI
4	Cai QQ, Dong YW, Wang R, Qi B, Guo JX, Pan J, Liu YY, Zhang CY and Wu XZ: MiR-124 inhibits the migration and invasion of human hepatocellular carcinoma cells by suppressing integrin αV expression. Sci Rep. 7:407332017. View Article : Google Scholar : PubMed/NCBI
5	Kuo MT: Redox regulation of multidrug resistance in cancer chemotherapy: Molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal. 11:99–133. 2009. View Article : Google Scholar : PubMed/NCBI
6	Blum HE: Hepatocellular carcinoma: Therapy and prevention. World J Gastroenterol. 11:7391–7400. 2005.PubMed/NCBI
7	Miska EA: How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev. 15:563–568. 2005. View Article : Google Scholar : PubMed/NCBI
8	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
9	Winter J, Jung S, Keller S, Gregory RI and Diederichs S: Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol. 11:228–234. 2009. View Article : Google Scholar : PubMed/NCBI
10	Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
11	Mendell JT: MicroRNAs: Critical regulators of development, cellular physiology and malignancy. Cell Cycle. 4:1179–1184. 2005. View Article : Google Scholar : PubMed/NCBI
12	Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M, et al: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
13	Zhan MN, Yu XT, Tang J, Zhou CX, Wang CL, Yin QQ, Gong XF, He M, He JR, Chen GQ, et al: MicroRNA-494 inhibits breast cancer progression by directly targeting PAK1. Cell Death Dis. 8:e25292017. View Article : Google Scholar : PubMed/NCBI
14	Yu G, Jia Z and Dou Z: miR-24-3p regulates bladder cancer cell proliferation, migration, invasion and autophagy by targeting DEDD. Oncol Rep. 37:1123–1131. 2017.PubMed/NCBI
15	Lee SW, Park KC, Kim JG, Moon SJ, Kang SB, Lee DS, Sul HJ, Ji JS and Jeong HY: Dysregulation of MicroRNA-196b-5p and MicroRNA-375 in Gastric Cancer. J Gastric Cancer. 16:221–229. 2016. View Article : Google Scholar : PubMed/NCBI
16	Dai L, Wang Y, Chen L, Zheng J, Li J and Wu X: MiR-221, a potential prognostic biomarker for recurrence in papillary thyroid cancer. World J Surg Oncol. 15:112017. View Article : Google Scholar : PubMed/NCBI
17	Yu M, Xue H, Wang Y, Shen Q, Jiang Q, Zhang X, Li K, Jia M, Jia J, Xu J, et al: miR-345 inhibits tumor metastasis and EMT by targeting IRF1-mediated mTOR/STAT3/AKT pathway in hepatocellular carcinoma. Int J Oncol. 50:975–983. 2017.PubMed/NCBI
18	Zhou Y, Wu D, Tao J, Qu P, Zhou Z and Hou J: MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer. Scand J Urol. 47:423–432. 2013. View Article : Google Scholar : PubMed/NCBI
19	Ventura A and Jacks T: MicroRNAs and cancer: Short RNAs go a long way. Cell. 136:586–591. 2009. View Article : Google Scholar : PubMed/NCBI
20	Sun C, Huang C, Li S, Yang C, Xi Y, Wang L, Zhang F, Fu Y and Li D: Hsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development. Oncotarget. 7:8341–8359. 2016. View Article : Google Scholar : PubMed/NCBI
21	Wu L, Hui H, Wang LJ, Wang H, Liu QF and Han SX: MicroRNA-326 functions as a tumor suppressor in colorectal cancer by targeting the nin one binding protein. Oncol Rep. 33:2309–2318. 2015.PubMed/NCBI
22	Zhang ZL, Bai ZH, Wang XB, Bai L, Miao F and Pei HH: miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells. PLoS One. 10:e01188142015. View Article : Google Scholar : PubMed/NCBI
23	Liang Z, Wu H, Xia J, Li Y, Zhang Y, Huang K, Wagar N, Yoon Y, Cho HT, Scala S, et al: Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol. 79:817–824. 2010. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
25	Wang B, Feng P, Xiao Z and Ren EC: LIM and SH3 protein 1 (Lasp1) is a novel p53 transcriptional target involved in hepatocellular carcinoma. J Hepatol. 50:528–537. 2009. View Article : Google Scholar : PubMed/NCBI
26	Wang H, Li W, Jin X, Cui S and Zhao L: LIM and SH3 protein 1, a promoter of cell proliferation and migration, is a novel independent prognostic indicator in hepatocellular carcinoma. Eur J Cancer. 49:974–983. 2013. View Article : Google Scholar : PubMed/NCBI
27	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
28	Zhang J, Zhou ZG, Huang ZX, Yang KL, Chen JC, Chen JB, Xu L, Chen MS and Zhang YJ: Prospective, single-center cohort study analyzing the efficacy of complete laparoscopic resection on recurrent hepatocellular carcinoma. Chin J Cancer. 35:252016. View Article : Google Scholar : PubMed/NCBI
29	El-Serag HB and Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
30	Yang J, Han S, Huang W, Chen T, Liu Y, Pan S and Li S: A meta-analysis of microRNA expression in liver cancer. PLoS One. 9:e1145332014. View Article : Google Scholar : PubMed/NCBI
31	Mao B and Wang G: MicroRNAs involved with hepatocellular carcinoma (Review). Oncol Rep. 34:2811–2820. 2015.PubMed/NCBI
32	Giordano S and Columbano A: MicroRNAs: New tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology. 57:840–847. 2013. View Article : Google Scholar : PubMed/NCBI
33	Zhou J, Xu T, Yan Y, Qin R, Wang H, Zhang X, Huang Y, Wang Y, Lu Y, Fu D, et al: MicroRNA-326 functions as a tumor suppressor in glioma by targeting the Nin one binding protein (NOB1). PLoS One. 8:e684692013. View Article : Google Scholar : PubMed/NCBI
34	Kefas B, Comeau L, Erdle N, Montgomery E, Amos S and Purow B: Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro-Oncol. 12:1102–1112. 2010. View Article : Google Scholar : PubMed/NCBI
35	Wang S, Lu S, Geng S, Ma S, Liang Z and Jiao B: Expression and clinical significance of microRNA-326 in human glioma miR-326 expression in glioma. Med Oncol. 30:3732013. View Article : Google Scholar : PubMed/NCBI
36	Li Y, Gao Y, Xu Y, Ma H and Yang M: Down-regulation of miR-326 is associated with poor prognosis and promotes growth and metastasis by targeting FSCN1 in gastric cancer. Growth Factors. 33:267–274. 2015. View Article : Google Scholar : PubMed/NCBI
37	Ji S, Zhang B, Kong Y, Ma F and Hua Y: MiR-326 inhibits gastric cancer cell growth through down regulating NOB1. Oncol Res. Oct 11–2016.(Epub ahead of print).
38	Cao L, Wang J and Wang PQ: MiR-326 is a diagnostic biomarker and regulates cell survival and apoptosis by targeting Bcl-2 in osteosarcoma. Biomed Pharmacother. 84:828–835. 2016. View Article : Google Scholar : PubMed/NCBI
39	Yin S, Du W, Wang F, Han B, Cui Y, Yang D, Chen H, Liu D, Liu X and Jiang C: MicroRNA-326 sensitizes human glioblastoma cells to curcumin via the SHH/GLI1 signaling pathway. Cancer Biol Ther. Nov 7–2016.(Epub ahead of print). View Article : Google Scholar :
40	Du W, Liu X, Chen L, Dou Z, Lei X, Chang L, Cai J, Cui Y, Yang D, Sun Y, et al: Targeting the SMO oncogene by miR-326 inhibits glioma biological behaviors and stemness. Neuro-Oncol. 17:243–253. 2015. View Article : Google Scholar : PubMed/NCBI
41	Li D, Du X, Liu A and Li P: Suppression of nucleosome-binding protein 1 by miR-326 impedes cell proliferation and invasion in non-small cell lung cancer cells. Oncol Rep. 35:1117–1124. 2016.PubMed/NCBI
42	Wang R, Chen X, Xu T, Xia R, Han L, Chen W, De W and Shu Y: MiR-326 regulates cell proliferation and migration in lung cancer by targeting phox2a and is regulated by HOTAIR. Am J Cancer Res. 6:173–186. 2016.PubMed/NCBI
43	Li J, Li S, Chen Z, Wang J, Chen Y, Xu Z, Jin M and Yu W: miR-326 reverses chemoresistance in human lung adenocarcinoma cells by targeting specificity protein 1. Tumour Biol. 37:13287–13294. 2016. View Article : Google Scholar : PubMed/NCBI
44	Cai M, Wang Z, Zhang J, Zhou H, Jin L, Bai R and Weng Y: Adam17, a Target of Mir-326, Promotes Emt-Induced Cells Invasion in Lung Adenocarcinoma. Cell Physiol Biochem. 36:1175–1185. 2015. View Article : Google Scholar : PubMed/NCBI
45	Tomasetto C, Moog-Lutz C, Régnier CH, Schreiber V, Basset P and Rio MC: Lasp-1 (MLN 50) defines a new LIM protein subfamily characterized by the association of LIM and SH3 domains. FEBS Lett. 373:245–249. 1995. View Article : Google Scholar : PubMed/NCBI
46	Grunewald TG and Butt E: The LIM and SH3 domain protein family: Structural proteins or signal transducers or both? Mol Cancer. 7:312008. View Article : Google Scholar : PubMed/NCBI
47	Wang C, Zheng X, Shen C and Shi Y: MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res. 31:582012. View Article : Google Scholar : PubMed/NCBI
48	Du YY, Zhao LM, Chen L, Sang MX, Li J, Ma M and Liu JF: The tumor-suppressive function of miR-1 by targeting LASP1 and TAGLN2 in esophageal squamous cell carcinoma. J Gastroenterol Hepatol. 31:384–393. 2016. View Article : Google Scholar : PubMed/NCBI
49	Wang H, Shi J, Luo Y, Liao Q, Niu Y, Zhang F, Shao Z, Ding Y and Zhao L: LIM and SH3 protein 1 induces TGFβ-mediated epithelial-mesenchymal transition in human colorectal cancer by regulating S100A4 expression. Clin Cancer Res. 20:5835–5847. 2014. View Article : Google Scholar : PubMed/NCBI
50	Zhao T, Ren H, Li J, Chen J, Zhang H, Xin W, Sun Y, Sun L, Yang Y, Sun J, et al: LASP1 is a HIF1α target gene critical for metastasis of pancreatic cancer. Cancer Res. 75:111–119. 2015. View Article : Google Scholar : PubMed/NCBI
51	Hailer A, Grunewald TG, Orth M, Reiss C, Kneitz B, Spahn M and Butt E: Loss of tumor suppressor mir-203 mediates overexpression of LIM and SH3 Protein 1 (LASP1) in high-risk prostate cancer thereby increasing cell proliferation and migration. Oncotarget. 5:4144–4153. 2014. View Article : Google Scholar : PubMed/NCBI
52	Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Uchida Y, Kawahara K, Nishiyama K, Seki N and Nakagawa M: Functional role of LASP1 in cell viability and its regulation by microRNAs in bladder cancer. Urol Oncol. 30:434–443. 2012. View Article : Google Scholar : PubMed/NCBI
53	Grunewald TG, Kammerer U, Schulze E, Schindler D, Honig A, Zimmer M and Butt E: Silencing of LASP-1 influences zyxin localization, inhibits proliferation and reduces migration in breast cancer cells. Exp Cell Res. 312:974–982. 2006. View Article : Google Scholar : PubMed/NCBI
54	Zhao L, Wang H, Liu C, Liu Y, Wang X, Wang S, Sun X, Li J, Deng Y, Jiang Y, et al: Promotion of colorectal cancer growth and metastasis by the LIM and SH3 domain protein 1. Gut. 59:1226–1235. 2010. View Article : Google Scholar : PubMed/NCBI
55	Salvi A, Bongarzone I, Ferrari L, Abeni E, Arici B, De Bortoli M, Scuri S, Bonini D, Grossi I, Benetti A, et al: Molecular characterization of LASP-1 expression reveals vimentin as its new partner in human hepatocellular carcinoma cells. Int J Oncol. 46:1901–1912. 2015.PubMed/NCBI